CClinicalTrials.gg
Status unknownNCT03220503Updated Jul 18, 2017

Effect of Endometrial Injury Before Frozen Embryo Transfer on Pregnancy Rate

A Phase 4 interventional study of endometrial injury in Infertility, sponsored by Ain Shams Maternity Hospital. Status unknown at 1 site in Egypt. Open to female participants aged Up to 40 Years. Per ClinicalTrials.gov, last updated 2017-07-18.

Sponsored by Ain Shams Maternity Hospital · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2017, registered Jun 2017).
Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
Up to 40 Years
Sex
Female
01

Study summary

Research Question:

In women undergoing frozen embryo transfer, does routine endometrial injury before frozen embryo transfer increase clinical pregnancy rate?

Research Hypothesis:

(Null Hypothesis) In women undergoing frozen embryo transfer Routine endometrial injury before frozen embryo transfer does not increase clinical pregnancy rate.

(Alternative Hypothesis) In women undergoing frozen embryo transfer, endometrial injury before the transfer may increase pregnancy rate.

Read the detailed description

Suitable women will be invited to participate in the study then a signed and informed consent will be obtained from them. When the patient's consent is obtained, they are to be included into the study.

Data Collection:

During first visit, all patients will undergo complete clinical examination and detailed medical history will be obtained. Each patient will have a Case Record Form (CRF) in which the following data will be recorded.

  • Patient number (according to the randomization schedule).
  • Age, BMI.
  • Past medical and surgical history.
  • Duration of infertility.

Procedure:

Endometrial injury:

A single induced injury will be done on the posterior endometrium on day 7 of the transfer cycle by using modified Cook catheter Protocol for vitrification Embryos will first loaded with equilibrium solution containing7.5% ethylene glycol (EG) and 7.5% dimethyl sulphoxide (DSMO) (Sigma-Aldrich) for 5-10 minute at room temperature and then with vitrification solution containing 15% EG, 15% DSMO and 0.5 mol/L sucrose for 50-60 seconds at room temperature. After observed cellular shrinkage, embryos will quickly stored in liquid nitrogen (LN) for at least 2 months. At warming, embryos will removed from LN and embryos will exposed to thawing solution containing sucrose at 37°C temperature for 50-60 seconds and then embryos will sequentially incubated in diluents solutions before being transferred .

Evaluation and transfer of thawed embryos After thawing, each embryo will evaluated twice, once immediately for the number of surviving blastomeres and again after 18 hours post-thaw in vitro culture for assessing of mitosis and number of blastomeres. Embryos will considered survived if >50% of each blastomere are intact and selected for intrauterine transfer (Depending on patients' embryos, 2 or 3 embryos will transferred).

Embryos will classified as fully intact or excellent morphology (100% cells survived with \<10% fragmentation) or good morphology (100% cells survived with 10%-20% fragmentation), partially damaged or poor morphology (≥50% cells survived with or without any fragmentation) and Degenerated embryos (\<50% cells survived) .Only fully intact and partially damaged embryos will transferred. Degenerated or arrested embryos will not transferred.

Protocol of endometrial preparation before Frozen Embryo Transfer (FET) :

There are different protocols for FET cycles. That is true for both "natural cycle" FETs and for "hormone replacement cycle" frozen-thawed embryo transfers. We will use hormone replacement cycles because they have better success rates. However, some clinics offer a natural cycle FET approach. Success rates are higher with hormone replacement, or "controlled" FET cycles.

Medicines and Drugs in a Frozen Embryo Transfer FET Cycle

  1. Gonadotropin-Releasing Hormone agonist (such as Lupron) will be given, either midluteal (day 21) or overlapping with a birth control pill.
  2. Down-regulation will be confirmed by ultrasound and blood tests.
  3. Estradiol valerate 2 mg twice daily (orally) will start after the period. This dose may need to be increased after monitoring of the uterine lining thickness.
  4. When the endometrium has a "good" thickness( > 8 mm), progesterone will be started (intramuscular shots, or a vaginal product).
  5. Embryo transfer will be planned for 3-6 days later - depending on the stage of development of the embryos to be transferred.
  6. Estrogen and progesterone will be continued in the luteal phase.
  7. Pregnancy testing will be done 9-14 days after transfer - depending on the stage of development of the embryos replaced and the preferences of the fertility clinic.
  8. If pregnant, estrogen and progesterone will be continued until about 10-15 weeks of pregnancy and then weaned off.
02

Conditions studied

  • Infertility

Browse trials for

03

In context

Infertility

2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.

This study's planned enrollment of 50 is below the median of 120 across 1,698 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Ain Shams Maternity Hospital is the lead sponsor of 135 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • All infertile women have high quality frozen embryos.

Exclusion criteria

Exclusion Criteria:

  • History of endocrine disease such as: diabetes; Hyperthyroidism and Hyperprolactinemia.
  • History of hysteroscopic surgery due to intrauterine adhesions.
  • History of cardiovascular, renal or liver disease .
  • History of stroke or myocardial infarction.
  • Poor quality embryos.
  • Alcohol or Substance abuse.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Group (A)

    consists of 25 patients will receive frozen embryo with endometrial scratching on day 7 of transfer cycle.

    Procedure: endometrial injury

  • No intervention
    Group (B)

    consists of 25 patients will receive frozen embryo without endometrial scratching as control group.

Interventions

  • Procedureendometrial injury

    single induced injury will be done on the posterior endometrium on day 7 of the transfer cycle by using modified Cook catheter.

06

What researchers measure

Primary outcomes

  1. Chemical pregnancy rate

    serum Beta -Human Chorionic Gonadotropin positive

    Time frame: two weeks after frozen embryo transfer

Secondary outcomes

  1. Clinical pregnancy rate

    appearance of gestational sac on trans-vaginal ultrasound

    Time frame: four weeks after frozen embryo transfer

07

Study locations

1 of 1 sites recruiting
  • ART unit - Ain Shams university Matrnity Hospital
    Cairo, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03220503
Lead sponsor
Ain Shams Maternity Hospital
Responsible party
Yasser sherbiny (Principal Investigator, Ain Shams Maternity Hospital) — Principal investigator
First posted
Jul 18, 2017
Start date
Mar 8, 2017
Primary completion
Sep 9, 2017 (estimated)
Completion
Oct 1, 2017 (estimated)
Last update
Jul 18, 2017

Study contacts

Yasser Sherbiny, invistgator
Contact
drysherbiny89@gmail.com
+201008961189
Adel Sh Salah El-Din, Ass. Prof.
study director · Ain Shams University
Mohammed A Faris, Lecturer
study director · Ain Shams University
Mohamed E Shawky, Lecturer
study director · Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion